Ds Healthcare Group, Inc. Receivables Turnover Ratio (DSKX), from the second quarter 2017 to the second quarter 2016 current and historic results, rankings and more - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Ds Healthcare Group, Inc.  (DSKX)
 

Ds Healthcare Group Accounts Receivables Turnover Ratio from the second quarter 2017 to the second quarter 2016

Quarterly Results, Trends, Rankings, Statistics


Ds Healthcare Group, Inc.'s ability to collect accounts receivable sequentially worsen to 6.56, pointing to a challenging and on top of that deteriorating business climate for the Biotechnology & Pharmaceuticals industry. Ds Healthcare Group's Accounts Receivable average collection period in the Jun 30 2017 quarter, has increased to 56 days, from 45 days, in the Mar 31 2017 quarter.

If we take a look into Healthcare sector 109 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Jun 30 2017 from 317 to 1358.

What is Receivable Turnover Ratio?
What is Ds Healthcare Group, Inc. Selling?


What is Receivable Turnover Ratio?




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

DSKX Receivables Turnover Ratio (Jun 30 2017)
II. Quarter		 (Mar 31 2017)
I. Quarter		 (Dec 31 2016)
IV. Quarter		 (Sep 30 2016)
III. Quarter		 (Jun 30 2016)
II. Quarter
Y / Y Receivable Change -6.82 % -29.94 % 62.2 % -27.14 % -17.44 %
Y / Y Revenue Change -53.97 % -9.92 % 84.99 % -14.23 % 46.62 %
Receivable Turnover Ratio (TTM) 6.56 8.11 7.83 8.16 7.79
DSKX's Total Ranking # 1358 # 317 # 310 # 1795 #
Accounts Receivable average collection period days 56 45 47 45 47
Seq. Receivable Change 85.14 % -67.88 % 91.29 % -18.08 % 39.2 %
Seq. Revenue Change 6.48 % -32.47 % 15.93 % -44.78 % 108.38 %


Receivable Turnover Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 9
Healthcare Sector # 110
Overall Market # 1358

Receivable Turnover Ratio Statistics
High Average Low
9.74 6.72 5.2
(Mar 31 2017)   (Dec 31 2012)





DSKX Company Profile • Back to DSKX Efficiency Comparisons • Compare DSKX Receivables Turnover Ratio to its Competitors

Financial Statements
Ds Healthcare Group's Accounts Receivable $ 2 Millions Visit DSKX's Balance sheet
Ds Healthcare Group's Sales TTM $ 10 Millions Visit DSKX's Income Statement
Sources of DSKX's Revenues Visit DSKX's Sales by Geography

Other Accounts Receivable Turnover Ratios
Biotechnology & Pharmaceuticals Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
DSKX's Receivable Turnover Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
DSKX's Growth Rates DSKX's Roa DSKX's Inventory Turnover Ratio DSKX's Dividend Comparisons
DSKX's Profitability Ratios DSKX's Roi DSKX's Asset Turnover Ratio DSKX's Dividend Growth
DSKX's Valuation Ratios DSKX's Roe DSKX's Financial Strength Ratios DSKX's Dividend Payout Ratio



Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2017, within Healthcare Sector Receivable Turnover Ratio Revenues for 12 Months ending Jun 30 2017 Receivable at quarter ending Jun 30 2017
Cardiff Lexington Corporation  18.46 $ 1.673  Millions$ 0.091  Millions
Biocorrx Inc   18.31 $ 0.628  Millions$ 0.034  Millions
Kadmon holdings inc   18.05 $ 18.495  Millions$ 1.025  Millions
Regenxbio Inc   17.77 $ 8.838  Millions$ 0.497  Millions
Acceleron Pharma inc  17.40 $ 13.136  Millions$ 0.755  Millions
Cv Sciences Inc   17.02 $ 13.274  Millions$ 0.780  Millions
Parallax Health Sciences Inc   16.93 $ 10.519  Millions$ 0.621  Millions
Dyne Therapeutics Inc   16.72 $ 6,667.000  Millions$ 398.750  Millions
Opiant Pharmaceuticals Inc   16.58 $ 18.446  Millions$ 1.112  Millions
Procyon Corporation  16.55 $ 4.012  Millions$ 0.242  Millions
Rayont Inc   15.81 $ 0.857  Millions$ 0.054  Millions
Icagen, Inc.  15.62 $ 21.532  Millions$ 1.378  Millions
Novocure Limited  15.62 $ 125.172  Millions$ 8.013  Millions
Arena Pharmaceuticals Inc   15.23 $ 87.419  Millions$ 5.741  Millions
Nektar Therapeutics  14.95 $ 133.103  Millions$ 8.902  Millions
Lexicon Pharmaceuticals Inc   14.76 $ 81.100  Millions$ 5.494  Millions
Chemed Corporation  14.51 $ 1,617.006  Millions$ 111.415  Millions
Kyntra Bio Inc   14.04 $ 120.454  Millions$ 8.580  Millions
Heartbeam Inc   14.03 $ 221.022  Millions$ 15.759  Millions
Integrated Biopharma Inc  13.78 $ 46.954  Millions$ 3.407  Millions
Davita Inc   13.77 $ 25,151.504  Millions$ 1,827.187  Millions
Scorpius Holdings inc   13.74 $ 0.777  Millions$ 0.057  Millions
Caredx Inc   13.69 $ 46.964  Millions$ 3.430  Millions
Proteo Inc  13.62 $ 0.259  Millions$ 0.019  Millions
Logicmark Inc  13.54 $ 21.993  Millions$ 1.624  Millions
Vivus Inc  13.46 $ 133.397  Millions$ 9.914  Millions
Aspira Women s Health inc   12.90 $ 3.052  Millions$ 0.237  Millions
Kineta Inc   12.44 $ 7.943  Millions$ 0.638  Millions
International Stem Cell Corporation  12.39 $ 7.400  Millions$ 0.597  Millions
Tearlab Corp  12.36 $ 28.059  Millions$ 2.270  Millions

Date modified: 2026-09-08T15:08:55+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.